Home Sequential Compression Devices Market Size, Trends and Growth Analysis by 2027

The market for home sequential compression devices was valued at approximately US$ 992.49 million in 2021 and is projected to grow to US$ 1,572.81 million by 2028, reflecting a compound annual growth rate (CAGR) of 6.8% from 2021 to 2028.

Several factors are contributing to this market expansion, including the increasing incidence of lymphatic and venous disorders, along with heightened awareness regarding advanced treatment options that incorporate sequential compression devices. However, the presence of alternative therapies poses a challenge to market growth.

Sequential compression devices (SCDs) play a crucial role in the prevention and management of venous thromboembolism (VTE). According to the Centers for Disease Control and Prevention (CDC), VTE occurs when a blood clot forms in a deep vein, primarily affecting the lower leg, thigh, or pelvis. Key risk factors for clot formation include vein injuries, sluggish blood flow, elevated estrogen levels, heart conditions, and obesity. A study published by StatPearls Publishing LLC in August 2020 indicates that over 200,000 individuals in the United States develop venous thrombosis each year. Additionally, Thrombosis UK reports that approximately 1 in 1000 people experience venous thrombosis annually. Factors contributing to venous disorders include pregnancy, obesity, varicose veins, and venous insufficiency. During pregnancy, venous insufficiency can occur due to the pressure from an enlarged uterus, which leads to increased blood pressure in the lower extremity veins and hormonal changes that weaken vein walls. Consequently, the rising prevalence of lymphatic and venous disorders is significantly driving the demand for home sequential compression devices, thus propelling market growth.

The global outbreak of the coronavirus disease 2019 (COVID-19) has diverted healthcare resources, including workforce, essential supplies, and intensive care unit (ICU) facilities, towards managing patients infected with the SARS-CoV-2 virus. As a result, many elective surgeries and interventions in various European nations have been postponed, with operating room resources redirected to pandemic management. Restrictions on personal interactions and the need for social distancing have also affected patient access to care. Despite these challenges, individuals with venous and lymphatic disorders still require specialized care. Furthermore, emerging evidence suggests that COVID-19 may increase the risk of both arterial and venous thromboembolic diseases, complicating the prognosis for affected patients. To address these challenges, the European Venous Forum (EVF) and the European College of Phlebology (ECoP), in collaboration with international organizations, have developed the Venous and Lymphatic Triage and Acuity Scale (VELTAS) to streamline and standardize patient management during this critical time. Such developments are likely to enhance the adoption of home sequential compression devices and positively influence market dynamics.

The home sequential compression devices market is categorized by device type into alternate sequential compression devices (ASCD) and simultaneous sequential compression devices (SSCD). In 2021, the SSCD segment held the largest market share and is expected to exhibit the highest CAGR during the forecast period.

When classified by type, the market is divided into standard and portable devices. The standard segment is anticipated to dominate the market in 2021 and is projected to experience the fastest growth rate in the coming years.

In terms of application, the market is segmented into deep vein thrombosis (DVT), lymphedema management, chronic venous insufficiency (CVI), and others. The DVT segment is expected to hold the largest market share in 2021 and is also predicted to register the highest CAGR throughout the forecast period.

Key organizations and regulatory bodies such as the World Health Organization (WHO), European Union Food and Drug Administration (FDA), China National Committee on Aging, NHS (National Health Service), and the Social Sciences and Humanities Research Council have been significant sources of information for this report.